Press Releases Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Real-time Estimate Cboe BZX Other stock markets 09:11:01 14/05/2024 pm IST			5-day change	1st Jan Change
4.885 ^USD	-0.10%		-5.89%	-25.65%

08/05	Earnings Flash (ZVRA) ZEVRA THERAPEUTICS Reports Q1 Revenue $3.4M	MT
08/05	Transcript : Zevra Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zevra Therapeutics to Participate at Upcoming Investor Events	09/05	AQ
Zevra Therapeutics: Q1 Earnings Snapshot	08/05	AQ
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates	08/05	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	07/05	PR
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024	01/05	AQ
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024	29/04	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	28/04	PR
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	20/04	PR
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting	16/04	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	12/04	PR
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility	10/04	AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA	05/04	PR
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates	29/03	AQ
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia	27/03	AQ
Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	26/03	AQ
Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024	18/03	AQ
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C	04/03	AQ
Zevra Therapeutics to Participate at Upcoming Investor Conferences	28/02	AQ
Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02	AQ
Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors	23/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Zevra Therapeutics, Inc.

Equities

ZVRA

US4884452065

Press Releases

Filters